This content is machine translated Guselkumab in psoriatic arthritis Early response predicted Recent analyses of a heterogeneous group of patients with active psoriatic arthritis (PsA) show that early treatment response with respect to skin psoriasis and enthesitis is a predictor of sustained…
View Post 4 min This content is machine translated Psoriatic arthritis (PsA) Guselkumab in joint involvement – successful interim results Long-term data from the pivotal DISCOVER-2 study show that treatment with guselkumab resulted in sustained improvements in joint and skin symptoms and functional capacity over a two-year period in biologic-naïve…
View Post 4 min This content is machine translated Guselkumab Study success: application for admission to PsoA submitted New Phase III data from the DISCOVER-1 and DISCOVER-2 studies show improvement in joint and skin symptoms of psoriatic arthritis at week 52, and an indication expansion of guselkumab is…
